943 related articles for article (PubMed ID: 30446596)
1. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
[TBL] [Abstract][Full Text] [Related]
2. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
[TBL] [Abstract][Full Text] [Related]
6. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
[TBL] [Abstract][Full Text] [Related]
7. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
Pozo-Rosich P; Detke HC; Wang S; Doležil D; Li LQ; Aurora SK; Reuter U
Curr Med Res Opin; 2022 May; 38(5):731-742. PubMed ID: 35392739
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
Bangs ME; Kudrow D; Wang S; Oakes TM; Terwindt GM; Magis D; Yunes-Medina L; Stauffer VL
BMC Neurol; 2020 Jan; 20(1):25. PubMed ID: 31952501
[TBL] [Abstract][Full Text] [Related]
10. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
[TBL] [Abstract][Full Text] [Related]
11. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
[TBL] [Abstract][Full Text] [Related]
13. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.
Zhou J; Zhong L; Chowdhury D; Skorobogatykh K; Luo G; Yang X; Zhang M; Sun L; Liu H; Qian C; Yu S
J Headache Pain; 2023 Aug; 24(1):103. PubMed ID: 37542222
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
15. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
[TBL] [Abstract][Full Text] [Related]
16. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
[TBL] [Abstract][Full Text] [Related]
17. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
Reuter U; Lucas C; Dolezil D; Hand AL; Port MD; Nichols RM; Stroud C; Tockhorn-Heidenreich A; Detke HC
Adv Ther; 2021 Nov; 38(11):5465-5483. PubMed ID: 34542830
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
[TBL] [Abstract][Full Text] [Related]
20. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
